

# Daniel Shouval

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2639940/publications.pdf>

Version: 2024-02-01

243  
papers

21,169  
citations

31902

53  
h-index

9311

143  
g-index

255  
all docs

255  
docs citations

255  
times ranked

17202  
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. <i>Journal of Hepatology</i> , 2021, 74, 944-951.	1.8	168
2	Hepatitis A and E – Differences and commonalities. <i>Journal of Hepatology</i> , 2020, 72, 578-580.	1.8	6
3	The History of Hepatitis A. <i>Clinical Liver Disease</i> , 2020, 16, 12-23.	1.0	12
4	Induction of Functional Control in Chronic Hepatitis B Patients with Low Level HBsAg Using a Combination of a PreS1/S2/S HBV Vaccine (Sci-BVac™) and a Nucleoside Analogue. <i>Journal of Infectious Disease and Therapy</i> , 2019, 07, .	0.1	3
5	Immunization against Hepatitis A. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a031682.	2.9	14
6	Prevention of Hepatitis A. , 2019, , 91-102.		0
7	Viral envelope-specific antibodies in chronic hepatitis B virus infection. <i>Current Opinion in Virology</i> , 2018, 30, 48-57.	2.6	32
8	EASL Recognition Award Recipient 2018: Prof. Didier Samuel. <i>Journal of Hepatology</i> , 2018, 68, 876-877.	1.8	0
9	Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. <i>Journal of Hepatology</i> , 2018, 68, 167-184.	1.8	194
10	Hepatitis B Vaccines. , 2018, , 342-374.e17.		13
11	Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e306-e319.	4.6	63
12	Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 724-736.	1.4	50
13	Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups. <i>Journal of Infectious Diseases</i> , 2016, 215, jiw611.	1.9	9
14	Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 16.	1.7	9
15	Hepatitis E in Israel: A nation-wide retrospective study. <i>World Journal of Gastroenterology</i> , 2016, 22, 5568.	1.4	7
16	Acute hepatitis E virus in pregnant women in Israel and in other industrialized countries. <i>Journal of Clinical Virology</i> , 2015, 73, 20-24.	1.6	28
17	Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine. <i>Medical Microbiology and Immunology</i> , 2015, 204, 57-68.	2.6	116
18	Hepatotoxicity of herbal and dietary supplements: an update. <i>Archives of Toxicology</i> , 2015, 89, 851-865.	1.9	109

#	ARTICLE	IF	CITATIONS
19	Expanding the donor pool for liver transplant recipients using HBsAg positive grafts. <i>Journal of Hepatology</i> , 2014, 61, 717-719.	1.8	6
20	Transcatheter chemoembolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. <i>Liver International</i> , 2014, 34, 1109-1117.	1.9	19
21	The impact of chronic hepatitis C infection on the circadian clock and sleep. <i>Journal of Hepatology</i> , 2014, 60, 685-686.	1.8	1
22	Focus. <i>Journal of Hepatology</i> , 2014, 60, 239-240.	1.8	4
23	The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation. <i>Journal of Hepatology</i> , 2014, 61, 190-192.	1.8	0
24	Focusing on the past, present, and future of hepatology. <i>Journal of Hepatology</i> , 2014, 61, 1196-1198.	1.8	3
25	Commonly Found Variations/Mutations in the HBsAg of Hepatitis B Virus in the Context of Effective Immunization Programs: Questionable Clinical and Public Health Significance. <i>Journal of Virology</i> , 2014, 88, 6532-6532.	1.5	15
26	Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. <i>Vaccine</i> , 2014, 32, 5077-5082.	1.7	49
27	Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study. <i>Journal of Hepatology</i> , 2014, 60, 260-266.	1.8	26
28	Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. <i>Journal of Hepatology</i> , 2014, 60, 1127-1134.	1.8	45
29	The pros and cons of lamivudine vs. entecavir in decompensated or severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , 2014, 60, 1108-1109.	1.8	10
30	Hepatitis A Virus. , 2014, , 417-438.		3
31	Focus. <i>Journal of Hepatology</i> , 2013, 59, 643-645.	1.8	0
32	Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype. <i>Journal of Hepatology</i> , 2013, 59, 1153-1159.	1.8	88
33	Hepatitis B vaccines. , 2013, , 205-234.		13
34	Focus. <i>Journal of Hepatology</i> , 2013, 58, 1063-1064.	1.8	8
35	Focus. <i>Journal of Hepatology</i> , 2013, 59, 201-202.	1.8	1
36	Focus. <i>Journal of Hepatology</i> , 2013, 59, 1151-1152.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Focus. Journal of Hepatology, 2013, 58, 203-204.	1.8	0
38	Focus. Journal of Hepatology, 2013, 58, 641-642.	1.8	2
39	Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. Journal of Hepatology, 2013, 58, 1089-1095.	1.8	100
40	Immunosuppression and HBV Reactivation. Seminars in Liver Disease, 2013, 33, 167-177.	1.8	141
41	Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 2521.	1.4	49
42	Hepatitis A. , 2012, , 531-539.		2
43	New doubts about preventing HAV superinfection in chronic HCV. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 367-368.	8.2	4
44	Hepatocellular carcinoma. Lancet, The, 2012, 379, 1245-1255.	6.3	3,897
45	Tracing hepatitis B virus to the 16th century in a Korean mummy. Hepatology, 2012, 56, 1671-1680.	3.6	116
46	1030 TRANS-ARTERIAL CHEMO-EMBOLIZATION (TACE) IS SAFE AND EFFICIENT FOR ELDERLY PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): RESULTS FROM AN INTERNATIONAL META-DATABASE. Journal of Hepatology, 2012, 56, S403.	1.8	1
47	Focus. Journal of Hepatology, 2012, 57, 1161-1162.	1.8	1
48	Breastmilk Hepatitis A Virus RNA in Nursing Mothers with Acute Hepatitis A Virus Infection. Breastfeeding Medicine, 2012, 7, 313-315.	0.8	24
49	Focus. Journal of Hepatology, 2012, 56, 303-304.	1.8	0
50	Focus. Journal of Hepatology, 2012, 56, 751-752.	1.8	0
51	Focus. Journal of Hepatology, 2012, 56, 1219-1220.	1.8	1
52	Focus. Journal of Hepatology, 2012, 57, 233-234.	1.8	0
53	Focus. Journal of Hepatology, 2012, 57, 713-714.	1.8	3
54	Increased Prevalence of HBV Envelope Mutants in Taiwan: An Emerging Public Health Risk or a False Alarm?. Gastroenterology, 2012, 143, 290-293.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428.	13.9	1,466
56	Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2405-2416.	13.9	2,278
57	Focus. <i>Journal of Hepatology</i> , 2011, 54, 1-2.	1.8	18
58	Focus. <i>Journal of Hepatology</i> , 2011, 54, 189-190.	1.8	0
59	Focus. <i>Journal of Hepatology</i> , 2011, 54, 597-598.	1.8	0
60	Focus. <i>Journal of Hepatology</i> , 2011, 54, 1085-1086.	1.8	1
61	Focus. <i>Journal of Hepatology</i> , 2011, 55, 243-244.	1.8	0
62	Focus. <i>Journal of Hepatology</i> , 2011, 55, 741-742.	1.8	0
63	Focus. <i>Journal of Hepatology</i> , 2011, 55, 1169-1170.	1.8	4
64	Bacteremia and "Endotipsitis" following transjugular intrahepatic portosystemic shunting. <i>World Journal of Hepatology</i> , 2011, 3, 130.	0.8	14
65	Endotipsitis-persistent infection of transjugular intrahepatic portosystemic shunt: pathogenesis, clinical features and management. <i>Liver International</i> , 2010, 30, 175-183.	1.9	35
66	Strategies for Global Prevention of Hepatitis B Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2010, 659, 175-188.	0.8	9
67	The search for a new endpoint for antiviral prophylaxis in hepatitis B virus transplanted patients. <i>Digestive and Liver Disease</i> , 2010, 42, 537-538.	0.4	1
68	Focus. <i>Journal of Hepatology</i> , 2010, 52, 145-146.	1.8	0
69	Focus. <i>Journal of Hepatology</i> , 2010, 52, 467-468.	1.8	1
70	Focus. <i>Journal of Hepatology</i> , 2010, 52, 781-782.	1.8	0
71	Focus. <i>Journal of Hepatology</i> , 2010, 53, 219-220.	1.8	0
72	Focus. <i>Journal of Hepatology</i> , 2010, 53, 395-396.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Focus. Journal of Hepatology, 2010, 53, 591-592.	1.8	0
74	Focus. Journal of Hepatology, 2010, 53, 789.	1.8	1
75	591 TRANS ARTERIAL CHEMO-EMBOLIZATION (TACE) IS A SAFE AND EFFECTIVE TREATMENT FOR VERY ELDERLY PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC). Journal of Hepatology, 2010, 52, S233-S234.	1.8	0
76	EASL Clinical Practice Guidelines: Management of chronic hepatitis B. Journal of Hepatology, 2009, 50, 227-242.	1.8	1,710
77	Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy. Journal of Hepatology, 2009, 50, 289-295.	1.8	96
78	482 OUTCOME COMPARISON OF PERCUTANEOUS AND SURGICAL INTERVENTIONS IN PATIENTS WITH BUDD-CHIARI SYNDROME- A LONGITUDINAL SINGLE CENTER EXPERIENCE. Journal of Hepatology, 2009, 50, S181.	1.8	0
79	Hepatitis B Vaccines. , 2009, , 449-470.		1
80	What is the clinical significance of the high prevalence of occult hepatitis B in US liver transplant patients with chronic hepatitis C?. Liver Transplantation, 2008, 14, 418-419.	1.3	28
81	Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology, 2008, 48, 407-417.	3.6	79
82	Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. Journal of Viral Hepatitis, 2008, 15, 1-15.	1.0	92
83	More reports of potential hepatotoxicity of Herbalife products: Reply. Journal of Hepatology, 2008, 49, 290-291.	1.8	3
84	Herbalife revisited: Reply. Journal of Hepatology, 2008, 49, 293-294.	1.8	2
85	Î²-Glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: A novel adjuvant for HBV vaccination. Vaccine, 2008, 26, 2589-2595.	1.7	27
86	The global impact of vaccination against hepatitis B: A historical overview. Vaccine, 2008, 26, 6266-6273.	1.7	346
87	Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries. Occupational and Environmental Medicine, 2008, 65, 446-451.	1.3	52
88	Mathematical model of the antibody response to hepatitis B vaccines: Implications for reduced schedules. Vaccine, 2007, 25, 3705-3712.	1.7	17
89	Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity. Journal of Hepatology, 2007, 47, 514-520.	1.8	108
90	Adoptive transfer of immunity to HBV in liver transplant patients:A step forward toward the proof of concept for therapeutic vaccination or a transient immunologic phenomenon?. Liver Transplantation, 2007, 13, 14-17.	1.3	11

#	ARTICLE	IF	CITATIONS
91	Hepatitis A and B vaccination and public health. <i>Journal of Viral Hepatitis</i> , 2007, 14, 1-5.	1.0	18
92	Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2007, 136, 699-712.	1.2	293
93	45 Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(âˆ“) chronic hepatitis B patients (study ETV-027). <i>Journal of Hepatology</i> , 2006, 44, S21-S22.	1.8	25
94	733 Interim (week 12) phase 2b virological efficacy and safety results of albumin interferon Alpha-2b combined with ribavirin in genotype 1 chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2006, 44, S270.	1.8	4
95	Acute Hepatitis A Infection in Pregnancy Is Associated With High Rates of Gestational Complications and Preterm Labor. <i>Gastroenterology</i> , 2006, 130, 1129-1134.	0.6	137
96	Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. <i>Vaccine</i> , 2006, 24, 2781-2789.	1.7	116
97	Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1011-1020.	13.9	1,118
98	Graft-Versus-Host Disease and the Liver. , 2006, , 863-874.		0
99	Air transportation of patients with end-stage liver disease to distant liver transplantation centers. <i>Liver Transplantation</i> , 2005, 11, 650-655.	1.3	6
100	Incidence of Hepatitis A in Israel Following Universal Immunization of Toddlers. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 202.	3.8	216
101	The questionable role of immunization against hepatitis B in HBV infected liver transplant patients. <i>Journal of Hepatology</i> , 2005, 43, 203-206.	1.8	11
102	Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. <i>Clinical Transplantation</i> , 2004, 18, 415-422.	0.8	15
103	Prevention of hepatitis C virus infection*. <i>Journal of Viral Hepatitis</i> , 2004, 11, 198-205.	1.0	36
104	Development of a scaled up liver device incorporating cryo-preserved pig liver micro-organs. <i>Journal of Hepatology</i> , 2004, 41, 950-956.	1.8	7
105	REDUCED INCIDENCE OF HYPERURICEMIA, GOUT, AND RENAL FAILURE FOLLOWING LIVER TRANSPLANTATION IN COMPARISON TO HEART TRANSPLANTATION: A LONG-TERM FOLLOW-UP STUDY. <i>Transplantation</i> , 2004, 77, 1576-1580.	0.5	19
106	Late cytomegalovirus disease following liver transplantation. <i>Transplant International</i> , 2003, 16, 861-865.	0.8	36
107	Late cytomegalovirus infection occurring two or more years following liver transplantation: a report of seven cases and review of the literature. <i>Transplantation Proceedings</i> , 2003, 35, 663-664.	0.3	5
108	Hepatitis B vaccines. <i>Journal of Hepatology</i> , 2003, 39, 70-76.	1.8	181

#	ARTICLE	IF	CITATIONS
109	Liver micro-organs transcribe albumin and clotting factors and increase survival of 92% hepatectomized rats. <i>Journal of Hepatology</i> , 2003, 39, 552-558.	1.8	4
110	Universal hepatitis A vaccination of young children is leading to disappearance of hepatitis A in adolescents and adults. <i>Journal of Hepatology</i> , 2003, 38, 172-173.	1.8	1
111	Hepatitis A booster vaccination: is there a need?. <i>Lancet, The</i> , 2003, 362, 1065-1071.	6.3	235
112	Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. <i>Journal of Clinical Virology</i> , 2003, 27, 213-230.	1.6	155
113	Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. <i>American Journal of Gastroenterology</i> , 2003, 98, 151-159.	0.2	27
114	Title is missing!. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 224-228.	1.1	3
115	Adoptive immune transfer as a therapeutic approach for persistent hepatitis B virus infection. , 2003, , 71-75.		0
116	Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. <i>Gut</i> , 2002, 50, 95-99.	6.1	109
117	HCC: What's the score. <i>Gut</i> , 2002, 50, 749-750.	6.1	5
118	Prognosis of Symptomatic Versus Asymptomatic Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 75-81.	1.1	112
119	Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. <i>Blood</i> , 2002, 100, 391-396.	0.6	174
120	Late cytomegalovirus disease following liver transplantation. <i>Transplant International</i> , 2002, 16, 861-865.	0.8	11
121	Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties. <i>Hepatology</i> , 2002, 35, 673-679.	3.6	73
122	Seroconversion after the addition of famciclovir therapy in a child with hepatitis B virus infection after liver transplantation who developed lamivudine resistance. <i>Transplantation</i> , 2002, 73, 820-822.	0.5	5
123	Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. <i>Journal of Hepatology</i> , 2001, 34, 92-99.	1.8	46
124	Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. <i>Journal of Hepatology</i> , 2001, 34, 123-127.	1.8	65
125	Prophylactic lamivudine therapy may prevent immunosuppressive induced HBV reactivation in chronic carriers. <i>Journal of Hepatology</i> , 2001, 34, 153.	1.8	0
126	Hepatitis C Virus Infection in Employees of a Large University Hospital in Israel. <i>Infection Control and Hospital Epidemiology</i> , 2001, 22, 754-761.	1.0	15



#	ARTICLE	IF	CITATIONS
127	Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2001, 27, 183-190.	1.3	72
128	Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients. <i>Mediators of Inflammation</i> , 2001, 10, 253-258.	1.4	18
129	Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine. <i>Gut</i> , 2001, 48, 849-852.	6.1	92
130	Hyper-IL-6 Gene Therapy Reverses Fulminant Hepatic Failure. <i>Molecular Therapy</i> , 2001, 3, 683-687.	3.7	73
131	Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the Trimer mouse. <i>Hepatology</i> , 2000, 31, 480-487.	3.6	31
132	Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 2000, 26, 633-638.	1.3	48
133	Human Interleukin-6 Facilitates Hepatitis B Virus Infection in Vitro and in Vivo. <i>Virology</i> , 2000, 270, 299-309.	1.1	33
134	Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. <i>Hepatology</i> , 2000, 32, 1189-1195.	3.6	224
135	Preclinical Evaluation of Two Human Anti-Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV-Trimer Mouse Model and in HBV Chronic Carrier Chimpanzees. <i>Hepatology</i> , 2000, 32, 588-596.	3.6	82
136	Transient Transmission of Hepatitis C Virus from Mothers to Newborns. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2000, 19, 267-274.	1.3	29
137	Reply. <i>Journal of Infectious Diseases</i> , 2000, 182, 1005-1006.	1.9	2
138	Human liver micro-organs transcribe albumin and clotting factors in an in vivo perfusion model. <i>Gastroenterology</i> , 2000, 118, A1007.	0.6	0
139	Is universal vaccination against hepatitis B sufficient for control of HBV infection? Lessons from the immunization campaign in Italy. <i>Journal of Hepatology</i> , 2000, 33, 1009-1011.	1.8	7
140	Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2000, 32, 574-578.	1.8	58
141	Residual viral B particles at 10 years post transplantation in patients receiving long term anti-HBs immunoglobulins (HBIG). <i>Journal of Hepatology</i> , 2000, 32, 31.	1.8	0
142	HBIG in patients liver transplanted with HBc positive donors. <i>Journal of Hepatology</i> , 2000, 32, 44.	1.8	0
143	The trimera mouse system: A model for HCV infection and evaluation of antiviral drugs. <i>Journal of Hepatology</i> , 2000, 32, 172.	1.8	2
144	TT virus infection in Israeli patients with fulminant hepatic failure. <i>Vox Sanguinis</i> , 2000, 79, 242-5.	0.7	0

#	ARTICLE	IF	CITATIONS
145	Interference of Antibody Production to Hepatitis B Surface Antigen in a Combination Hepatitis A/Hepatitis B Vaccine. <i>Journal of Infectious Diseases</i> , 1999, 180, 2018-2022.	1.9	39
146	Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo. <i>Immunology</i> , 1999, 96, 634-641.	2.0	16
147	The hepatitis B virus-trimera mouse: A model for human HBV infection and evaluation of anti-HBV therapeutic agents. <i>Hepatology</i> , 1999, 29, 553-562.	3.6	97
148	Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. <i>Hepatology</i> , 1999, 29, 1299-1305.	3.6	33
149	“Silent” presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. <i>Hepatology</i> , 1999, 30, 1144-1150.	3.6	99
150	Comparison of immunogenicity of two hepatitis A vaccines “VAQTA” and HAVRIX” in young adults. <i>Vaccine</i> , 1999, 17, 2290-2296.	1.7	61
151	Hepatitis A vaccine for secondary hepatitis A infection. <i>Lancet</i> , The, 1999, 354, 342.	6.3	3
152	The role of ERCP in biliary complications after liver transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 1897-1898.	0.3	7
153	Will transplantation of an hepatitis C “infected graft improve the outcome of liver transplantation in HCV patients?. <i>Gastroenterology</i> , 1999, 117, 263-265.	0.6	17
154	Increased risk of exposure to hepatitis b infection among butchers sharing knives. <i>American Journal of Medicine</i> , 1999, 106, 479-480.	0.6	3
155	Vaccines for prevention of viral hepatitis. <i>Haemophilia</i> , 1998, 4, 587-594.	1.0	2
156	Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system. <i>Immunology</i> , 1998, 93, 154-161.	2.0	51
157	Psychological distress in patients with chronic, nonalcoholic, uncomplicated liver disease. <i>Journal of Psychosomatic Research</i> , 1998, 44, 547-554.	1.2	18
158	Liver Transplantation Across the ABO Barrier: The Role of Plasmapheresis. <i>Transplantation Proceedings</i> , 1998, 30, 701-703.	0.3	13
159	Octreotide in hepatocellular carcinoma. <i>Gut</i> , 1998, 42, 316-318.	6.1	6
160	Natural course of HCV viremia following liver transplantation and clinical course of reinfection. <i>Transplantation Proceedings</i> , 1997, 29, 2635-2639.	0.3	0
161	Natural course of de novo hepatitis B virus infection in liver transplant recipients. <i>Transplantation Proceedings</i> , 1997, 29, 2677-2679.	0.3	3
162	Should hepatitis B immunoglobulin therapy be discontinued after HBV reinfection following liver transplantation?. <i>Transplantation Proceedings</i> , 1997, 29, 2680-2683.	0.3	2

#	ARTICLE	IF	CITATIONS
163	Hepatitis-C-associated cryoglobulinemia after liver transplantation. Transplantation Proceedings, 1997, 29, 2684-2686.	0.3	4
164	Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen. Journal of Hepatology, 1997, 27, 170-175.	1.8	20
165	Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Digestive Diseases and Sciences, 1997, 42, 938-943.	1.1	19
166	Need for liver transplantation. Lancet, The, 1996, 348, 62-63.	6.3	3
167	Hepatitis A Prophylaxis. BioDrugs, 1996, 6, 261-272.	0.7	7
168	Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. Journal of Viral Hepatitis, 1996, 3, 37-42.	1.0	31
169	Esophageal Malignancy after Liver Transplantation in a Patient with Barrett's Esophagus. Scandinavian Journal of Gastroenterology, 1996, 31, 415-416.	0.6	19
170	Mononeuritis multiplex: a rare complication of acute hepatitis A. Liver, 1996, 16, 288-289.	0.1	8
171	Hepatitis A virus and polymerase chain reaction amplification. Blood Coagulation and Fibrinolysis, 1995, 6, S27-S31.	0.5	8
172	Aorto-atrial fistula following internal jugular vein catheterization. European Heart Journal, 1995, 16, 279-281.	1.0	13
173	Immunization against Hepatitis B through Adoptive Transfer of Immunity. Intervirology, 1995, 38, 41-46.	1.2	26
174	p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer, 1995, 75, 2420-2426.	2.0	46
175	Specific targeting of adriamycin conjugates with monoclonal antibodies to hepatoma associated antigens to intrahepatic tumors in athymic mice. Hepatology, 1995, 22, 1482-1487.	3.6	5
176	Correction of ?-glucuronidase deficiency in mice by intrasplenic transplantation of isolated hepatocytes. International Hepatology Communications, 1995, 3, 97-104.	0.7	0
177	Hepatitis C Virus Viremia in SCID -&gt; BNX Mouse Chimera. Journal of Infectious Diseases, 1995, 172, 25-30.	1.9	66
178	Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. Journal of Hepatology, 1995, 23, 98-101.	1.8	43
179	Adoptive transfer of immunity to hepatitis B: development of the concept and evolution of the research project for targeted immunotherapy against hepatic cells which express a viral antigen. Advanced Drug Delivery Reviews, 1995, 17, 317-320.	6.6	5
180	The need for liver transplantation: a nationwide estimate based on consensus review. Lancet, The, 1995, 346, 660-662.	6.3	12

#	ARTICLE	IF	CITATIONS
181	Exposure to hepatitis B and C and to HTLV-1 and 2 among Israeli drug abusers in Jerusalem. <i>Addiction</i> , 1994, 89, 869-874.	1.7	18
182	Hepatitis A Virus Infection among the Hemophilia Population at the Bonn Hemophilia Center. <i>Vox Sanguinis</i> , 1994, 67, 3-8.	0.7	42
183	Sequence Variability of Hepatitis A Virus and Factor VIII Associated Hepatitis A Infections in Hemophilia Patients in Europe: An Update. <i>Vox Sanguinis</i> , 1994, 67, 39-46.	0.7	30
184	Inactivation of Hepatitis A Virus by Pasteurization and Elimination of Picornaviruses during Manufacture of Factor VIII Concentrate. <i>Vox Sanguinis</i> , 1994, 67, 62-66.	0.7	15
185	A Double Virus-Inactivated Factor VIII Preparation: Validation and Biochemical Characteristics. <i>Vox Sanguinis</i> , 1994, 67, 67-68.	0.7	4
186	Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. <i>Vaccine</i> , 1994, 12, 1453-1459.	1.7	107
187	Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes. <i>Journal of Hepatology</i> , 1994, 20, 398-404.	1.8	44
188	Adoptive Transfer of Immunity to Hepatitis B Through Bone Marrow Transplantation from Immunized Donors. , 1994, , 158-161.		0
189	Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors. <i>Hepatology</i> , 1993, 17, 955-959.	3.6	47
190	A finger-stick assay for determination of immunity to hepatitis A: a preliminary report. <i>Journal of Hepatology</i> , 1993, 18, S27-S31.	1.8	2
191	Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. <i>Journal of Hepatology</i> , 1993, 18, S32-S37.	1.8	25
192	Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial. <i>Journal of Hepatology</i> , 1993, 18, S46-S50.	1.8	17
193	Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. <i>Journal of Hepatology</i> , 1993, 18, S51-S55.	1.8	72
194	Excessive Hepatitis-B Surface Antigen Production After Corticosteroids and the Development of Immunoblastic Lymphoma. <i>Leukemia and Lymphoma</i> , 1993, 10, 241-244.	0.6	6
195	Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. <i>Vaccine</i> , 1993, 11, S9-S14.	1.7	69
196	Sclerosing cholangitis associated with Crohn's disease and autoimmune haemolytic anaemia. <i>Postgraduate Medical Journal</i> , 1993, 69, 656-658.	0.9	18
197	Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. <i>Gastroenterology</i> , 1993, 104, 1818-1821.	0.6	135
198	Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. <i>Hepatology</i> , 1993, 18, 246-252.	3.6	11

#	ARTICLE	IF	CITATIONS
199	Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors. <i>Hepatology</i> , 1993, 17, 955-959.	3.6	3
200	IgA deficiency associated with chronic hepatitis C virus infection. A cause or an effect?. <i>Archives of Internal Medicine</i> , 1993, 153, 1588-1592.	4.3	1
201	Relapsing Hepatitis A Review of 14 Cases and Literature Survey. <i>Medicine (United States)</i> , 1992, 71, 14-23.	0.4	185
202	Liver Failure and the Sea-Blue Histocyte/Adult Niemann-Pick Disease. <i>Journal of Clinical Gastroenterology</i> , 1992, 15, 146-149.	1.1	22
203	Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.. <i>Journal of Epidemiology and Community Health</i> , 1992, 46, 587-594.	2.0	38
204	A Controlled Trial of a Formalin-Inactivated Hepatitis A Vaccine in Healthy Children. <i>New England Journal of Medicine</i> , 1992, 327, 453-457.	13.9	530
205	Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice. <i>Cancer Immunology, Immunotherapy</i> , 1992, 35, 186-192.	2.0	16
206	Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 1992, 35, 135-144.	2.0	13
207	SEROLOGICAL AND MOLECULAR ANALYSIS OF HLA IN ISRAELI PRIMARY SCLEROSING CHOLANGITIS PATIENTS. <i>International Journal of Immunogenetics</i> , 1992, 19, 295-302.	1.2	8
208	p53 mutation in hepatocellular carcinoma after aflatoxin exposure. <i>Lancet, The</i> , 1991, 338, 1356-1359.	6.3	436
209	Prevalence of HBsAg carriers in native and immigrant pregnant female populations in Israel and passive/active vaccination against HBV of newborns at risk. <i>Journal of Medical Virology</i> , 1991, 34, 217-222.	2.5	24
210	Localized primary sclerosing cholangitis mimicking a cholecystectomy stricture relieved by an endoprosthesis.. <i>Postgraduate Medical Journal</i> , 1991, 67, 482-484.	0.9	4
211	The effect of anti- $\alpha$ -fetoprotein-adriamycin conjugate on a human hepatoma. <i>Hepatology</i> , 1990, 11, 578-584.	3.6	18
212	A conjugate of 5-fluorouridine-poly(L-lysine) and an antibody reactive with human colon carcinoma. <i>Bioconjugate Chemistry</i> , 1990, 1, 285-290.	1.8	16
213	Postpartum Budd-Chiari syndrome with prolonged hypercoagulability state. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 162, 1164-1165.	0.7	20
214	Improvement of Immune-Complex Nephritis Associated with Hepatitis B Surface Antigen Excess. <i>American Journal of Nephrology</i> , 1989, 9, 162-166.	1.4	7
215	A Common-Source Outbreak of Fulminant Hepatitis B in a Hospital. <i>Annals of Internal Medicine</i> , 1989, 110, 691.	2.0	89
216	In Vivo expression of two novel tumor-associated antigens and their use in immunolocalization of human hepatocellular carcinoma. <i>Hepatology</i> , 1989, 9, 625-634.	3.6	31

#	ARTICLE	IF	CITATIONS
217	Hepatitis during measles in young adults: Possible role of antipyretic drugs. <i>Hepatology</i> , 1989, 10, 203-206.	3.6	22
218	Detection of hepatitis a virus rna in serum from patients with acute hepatitis. <i>Journal of Medical Virology</i> , 1989, 28, 261-263.	2.5	16
219	Radioimmunolocation of Hepatic and Pulmonary Metastasis of Human Colon Adenocarcinoma. <i>Gastroenterology</i> , 1989, 96, 1317-1329.	0.6	17
220	Comparative morphology and tumorigenicity of human hepatocellular carcinoma cell lines in athymic rats and mice. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1988, 412, 595-606.	1.4	26
221	An acupuncture-associated outbreak of hepatitis B in Jerusalem. <i>European Journal of Epidemiology</i> , 1988, 4, 322-325.	2.5	27
222	Sublines of the Burkitt line Daudi, selected on the basis of reactivity with soybean agglutinin, differ in tumorigenicity in athymic mice. <i>Immunology Letters</i> , 1988, 18, 173-179.	1.1	1
223	Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 8276-8280.	3.3	22
224	Production of Erythropoietin by an Established Human Renal Carcinoma Cell Line: In Vitro and In Vivo Studies. <i>Advances in Experimental Medicine and Biology</i> , 1988, 241, 319-328.	0.8	4
225	Clofibrate does not induce peroxisomal proliferation in human hepatoma cell lines PLC/PRF/5 and SK-HEP-1. <i>Cancer Letters</i> , 1987, 34, 263-272.	3.2	16
226	Conjugates between monoclonal antibodies to HBsAg and cytosine arabinoside. <i>Journal of Hepatology</i> , 1986, 3, S87-S95.	1.8	9
227	Continuous production of erythropoietin by an established human renal carcinoma cell line: development of the cell line.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 165-169.	3.3	32
228	Detection of alpha-foetoprotein messenger RNA in human hepatocellular carcinoma and hepatoblastoma tissue. <i>British Journal of Cancer</i> , 1986, 54, 779-785.	2.9	31
229	Development of a novel Clq immunoabsorbent for removal of circulating immunocomplexes: Quantitative isolation of hepatitis B virus surface antigen and immunocomplexes. <i>Immunology Letters</i> , 1985, 11, 1-8.	1.1	8
230	Human hepatoma-associated cell surface antigen: Identification and characterization by means of monoclonal antibodies. <i>Hepatology</i> , 1985, 5, 347-356.	3.6	28
231	Conservation from rat to human of cytosolic phosphoenol pyruvate carboxykinase and the control of its gene expression. <i>FEBS Letters</i> , 1985, 180, 175-180.	1.3	8
232	Antigenic characterization of human hepatocellular carcinoma. Development of in vitro and in vivo immunoassays that use monoclonal antibodies.. <i>Journal of Clinical Investigation</i> , 1985, 76, 40-51.	3.9	24
233	Detection and characterization of hepatitis B virus DNA in serum of HBe antigen-negative HBsAg carriers. <i>Journal of Medical Virology</i> , 1984, 14, 17-26.	2.5	53
234	Aortic Insufficiency Unmasked by a Peritoneovenous Shunt. <i>Annals of Internal Medicine</i> , 1983, 99, 129.	2.0	2

#	ARTICLE	IF	CITATIONS
235	Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus. <i>Journal of Clinical Investigation</i> , 1983, 72, 707-717.	3.9	29
236	Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1982, 79, 650-654.	3.3	25
237	Immunotherapy in nude mice of human hepatoma using monoclonal antibodies against hepatitis B virus. <i>Nature</i> , 1982, 298, 567-569.	13.7	40
238	Laboratory Stigmata of Connective Tissue Disorders in Asymptomatic Carriers of Hepatitis B Virus. <i>American Journal of the Medical Sciences</i> , 1981, 282, 116-119.	0.4	0
239	Integration of Hepatitis B Virus DNA into the Genome of Liver Cells in Chronic Liver Disease and Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 1981, 305, 1067-1073.	13.9	730
240	Chronic hepatitis in chimpanzee carriers of hepatitis B virus: morphologic, immunologic, and viral DNA studies.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1980, 77, 6147-6151.	3.3	47
241	Identification of integrated hepatitis B virus DNA and expression of viral RNA in an HBsAg-producing human hepatocellular carcinoma cell line. <i>Nature</i> , 1980, 286, 531-533.	13.7	246
242	Premature Appearance of Hepatic Phosphoenolpyruvate Carboxykinase in Fetal Rats, Not Mediated by Adenosine 3': 5'-Monophosphate. <i>FEBS Journal</i> , 1979, 102, 489-496.	0.2	22
243	EFFECT OF CO-TRIMOXAZOLE ON NORMAL CREATININE CLEARANCE. <i>Lancet, The</i> , 1978, 311, 244-245.	6.3	53